Comments on 2018 ESC/ESH Hypertension Guidelines: Chinese Perspective

Circ Res. 2019 Mar 29;124(7):978-980. doi: 10.1161/CIRCRESAHA.119.314997.

Authors

Yuqing Zhang¹, Wenzhong Zhang², Lisheng Liu¹

Affiliations

¹ From the Department of Cardiology, Fu Wai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China (Y.Z., L.L.).
² Department of Hypertension, Ruijin Hospital, Shanghai Jiaotong University, Shanghai Institute of Hypertension, China (W.Z.).

PMID: 30920922
DOI: 10.1161/CIRCRESAHA.119.314997

No abstract available

Keywords: blood pressure guideline; cardiovascular diseases; combination treatment; hypertension.

MeSH terms

Antihypertensive Agents / adverse effects
Antihypertensive Agents / therapeutic use*
Blood Pressure / drug effects*
China / epidemiology
Consensus
Humans
Hypertension / diagnosis
Hypertension / epidemiology
Hypertension / physiopathology
Hypertension / therapy*
Practice Guidelines as Topic*
Practice Patterns, Physicians' / standards*
Risk Assessment
Risk Factors
Risk Reduction Behavior*
Treatment Outcome

Substances

Antihypertensive Agents